Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders

Allogeneic hematopoietic cell transplant (HCT) is curative for pediatric patients with non-malignant hematopoietic disorders, including hemoglobinopathies, bone marrow failure syndromes, and primary immunodeficiencies. Early establishment of donor-derived innate and adaptive immunity following HCT i...

Full description

Bibliographic Details
Main Authors: Sima T. Bhatt, Jeffrey J. Bednarski
Format: Article
Language:English
Published: Frontiers Media S.A. 2020-08-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/article/10.3389/fimmu.2020.01988/full
_version_ 1828870263796662272
author Sima T. Bhatt
Jeffrey J. Bednarski
author_facet Sima T. Bhatt
Jeffrey J. Bednarski
author_sort Sima T. Bhatt
collection DOAJ
description Allogeneic hematopoietic cell transplant (HCT) is curative for pediatric patients with non-malignant hematopoietic disorders, including hemoglobinopathies, bone marrow failure syndromes, and primary immunodeficiencies. Early establishment of donor-derived innate and adaptive immunity following HCT is associated with improved overall survival, lower risk of infections and decreased incidence of graft failure. Immune reconstitution (IR) is impacted by numerous clinical variables including primary disease, donor characteristics, conditioning regimen, and graft versus host disease (GVHD). Recent advancements in HCT have been directed at reducing toxicity of conditioning therapy, expanding donor availability through use of alternative donor sources, and addressing morbidity from GVHD with novel graft manipulation. These novel transplant approaches impact the kinetics of immune recovery, which influence post-transplant outcomes. Here we review immune reconstitution in pediatric patients undergoing HCT for non-malignant disorders. We explore the transplant-associated factors that influence immunologic recovery and the disease-specific associations between IR and transplant outcomes.
first_indexed 2024-12-13T06:07:33Z
format Article
id doaj.art-c6cb96a20a03449e95897061c4a1a27b
institution Directory Open Access Journal
issn 1664-3224
language English
last_indexed 2024-12-13T06:07:33Z
publishDate 2020-08-01
publisher Frontiers Media S.A.
record_format Article
series Frontiers in Immunology
spelling doaj.art-c6cb96a20a03449e95897061c4a1a27b2022-12-21T23:57:11ZengFrontiers Media S.A.Frontiers in Immunology1664-32242020-08-011110.3389/fimmu.2020.01988567281Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant DisordersSima T. BhattJeffrey J. BednarskiAllogeneic hematopoietic cell transplant (HCT) is curative for pediatric patients with non-malignant hematopoietic disorders, including hemoglobinopathies, bone marrow failure syndromes, and primary immunodeficiencies. Early establishment of donor-derived innate and adaptive immunity following HCT is associated with improved overall survival, lower risk of infections and decreased incidence of graft failure. Immune reconstitution (IR) is impacted by numerous clinical variables including primary disease, donor characteristics, conditioning regimen, and graft versus host disease (GVHD). Recent advancements in HCT have been directed at reducing toxicity of conditioning therapy, expanding donor availability through use of alternative donor sources, and addressing morbidity from GVHD with novel graft manipulation. These novel transplant approaches impact the kinetics of immune recovery, which influence post-transplant outcomes. Here we review immune reconstitution in pediatric patients undergoing HCT for non-malignant disorders. We explore the transplant-associated factors that influence immunologic recovery and the disease-specific associations between IR and transplant outcomes.https://www.frontiersin.org/article/10.3389/fimmu.2020.01988/fullimmune reconstitutionhematopoietic stem cell transplantnon-malignant disordershemoglobinopathysevere combined immunodeficiencyaplastic anemia
spellingShingle Sima T. Bhatt
Jeffrey J. Bednarski
Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders
Frontiers in Immunology
immune reconstitution
hematopoietic stem cell transplant
non-malignant disorders
hemoglobinopathy
severe combined immunodeficiency
aplastic anemia
title Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders
title_full Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders
title_fullStr Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders
title_full_unstemmed Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders
title_short Immune Reconstitution in Pediatric Patients Following Hematopoietic Cell Transplant for Non-malignant Disorders
title_sort immune reconstitution in pediatric patients following hematopoietic cell transplant for non malignant disorders
topic immune reconstitution
hematopoietic stem cell transplant
non-malignant disorders
hemoglobinopathy
severe combined immunodeficiency
aplastic anemia
url https://www.frontiersin.org/article/10.3389/fimmu.2020.01988/full
work_keys_str_mv AT simatbhatt immunereconstitutioninpediatricpatientsfollowinghematopoieticcelltransplantfornonmalignantdisorders
AT jeffreyjbednarski immunereconstitutioninpediatricpatientsfollowinghematopoieticcelltransplantfornonmalignantdisorders